The beneficial effect of SGLT2 inhibitors in patients with HFpEF is currently under investigation (i.e., in the EMPOROR-Preserved, PRESERVED-HF and DELIVER trials). This evidence concerns the gene SLC5A2 and hydrops fetalis.